Total Payments
$1.2M
2024 Payments
$55,387
Companies
64
Transactions
1,413
Medicare Patients
12,963
Medicare Billing
$5.9M
Payment Breakdown by Category
Other$788,030 (65.3%)
Consulting$220,211 (18.3%)
Travel$165,983 (13.8%)
Food & Beverage$29,826 (2.5%)
Research$2,075 (0.2%)
Education$285.33 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $743,340 | 242 | 61.6% |
| Consulting Fee | $220,211 | 91 | 18.3% |
| Travel and Lodging | $165,983 | 406 | 13.8% |
| Honoraria | $44,224 | 14 | 3.7% |
| Food and Beverage | $29,826 | 641 | 2.5% |
| Unspecified | $2,075 | 1 | 0.2% |
| Long term medical supply or device loan | $465.76 | 5 | 0.0% |
| Education | $285.33 | 13 | 0.0% |
Payments by Type
General
$1.2M
1,412 transactions
Research
$2,075
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $265,727 | 280 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $244,182 | 168 | $0 (2024) |
| Exelixis Inc. | $237,960 | 206 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $130,063 | 161 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $104,810 | 106 | $0 (2024) |
| Dova Pharmaceuticals | $49,443 | 27 | $0 (2021) |
| Seagen Inc. | $35,973 | 37 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $33,987 | 29 | $0 (2024) |
| SOBI, INC | $25,501 | 20 | $0 (2024) |
| Seattle Genetics, Inc. | $9,326 | 25 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,387 | 49 | Takeda Pharmaceuticals U.S.A., Inc. ($29,132) |
| 2023 | $139,307 | 187 | E.R. Squibb & Sons, L.L.C. ($47,013) |
| 2022 | $190,216 | 237 | E.R. Squibb & Sons, L.L.C. ($63,243) |
| 2021 | $178,009 | 188 | Rigel Pharmaceuticals, Inc. ($61,647) |
| 2020 | $96,752 | 111 | Rigel Pharmaceuticals, Inc. ($20,270) |
| 2019 | $297,049 | 299 | Rigel Pharmaceuticals, Inc. ($68,030) |
| 2018 | $209,396 | 237 | Exelixis Inc. ($90,413) |
| 2017 | $40,294 | 105 | Novartis Pharmaceuticals Corporation ($25,790) |
All Payment Transactions
1,413 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $29.50 | General |
| Category: Oncology | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,220.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,148.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $915.00 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $558.96 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/24/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $347.84 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/24/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $108.66 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Consulting Fee | Cash or cash equivalent | $5,775.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,708.00 | General |
| Category: Oncology | ||||||
| 06/27/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $67.79 | General |
| Category: Oncology | ||||||
| 06/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,050.00 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $120.84 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,100.00 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.29 | General |
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: Oncology | ||||||
| 05/16/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 05/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $945.49 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $249.01 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $122.84 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Immunology | ||||||
| 04/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $716.48 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,450.00 | General |
| Category: Oncology | ||||||
| 04/22/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $2,075 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 42 | 2,816 | 121,753 | $6.8M | $1.5M |
| 2022 | 56 | 3,781 | 148,509 | $7.2M | $1.7M |
| 2021 | 61 | 3,874 | 237,067 | $8.5M | $1.9M |
| 2020 | 48 | 2,492 | 105,388 | $3.7M | $796,331 |
Total Patients
12,963
Total Services
612,717
Medicare Billing
$5.9M
Procedure Codes
210
All Medicare Procedures & Services
210 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 7,000 | $882,000 | $303,240 | 34.4% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 13 | 7,200 | $982,080 | $274,600 | 28.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 48 | 14,400 | $734,400 | $265,742 | 36.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 16 | 3,140 | $602,880 | $106,498 | 17.7% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 51 | 6,400 | $485,200 | $105,747 | 21.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 51 | 43,400 | $911,400 | $102,097 | 11.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 374 | 919 | $260,148 | $93,134 | 35.8% |
| J9034 | Injection, bendamustine hcl (bendeka), 1 mg | Office | 2023 | 11 | 5,753 | $385,451 | $74,525 | 19.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 109 | 438 | $300,468 | $48,544 | 16.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 238 | 330 | $63,297 | $23,070 | 36.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 75 | 107 | $41,259 | $15,077 | 36.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 34 | 9,880 | $88,920 | $13,548 | 15.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 406 | 1,732 | $60,620 | $13,128 | 21.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 17 | 79 | $311,102 | $10,710 | 3.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 103 | 197 | $59,888 | $10,423 | 17.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 88 | 340 | $51,680 | $8,297 | 16.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 298 | 817 | $15,523 | $6,855 | 44.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $17,650 | $6,166 | 34.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 28 | 89 | $18,245 | $5,607 | 30.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 91 | 412 | $43,260 | $5,346 | 12.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 42 | 88 | $29,392 | $4,907 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $14,396 | $4,808 | 33.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 131 | 425 | $39,525 | $4,766 | 12.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 30 | 108 | $16,848 | $2,595 | 15.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 14 | 16 | $8,368 | $2,274 | 27.2% |
About Dr. Yousuf Gaffar, MD
Dr. Yousuf Gaffar, MD is a Hematology & Oncology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1891798914.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yousuf Gaffar, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $55,387 received in 2024. These payments were reported across 1,413 transactions from 64 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($743,340).
As a Medicare-enrolled provider, Gaffar has provided services to 12,963 Medicare beneficiaries, totaling 612,717 services with total Medicare billing of $5.9M. Data is available for 4 years (2020–2023), covering 210 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Denver, CO
- Active Since 05/23/2005
- Last Updated 01/07/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1891798914
Products in Payments
- Tavalisse (Drug) $231,655
- OPDIVO (Biological) $220,801
- Cabometyx (Drug) $189,124
- CALQUENCE (Drug) $99,776
- MEKINIST (Drug) $78,268
- Doptelet (Drug) $53,480
- CABOMETYX (Drug) $44,829
- KISQALI (Drug) $40,367
- Rezlidhia (Drug) $34,072
- FRUZAQLA (Drug) $31,796
- ADCETRIS (Biological) $27,355
- DOPTELET (Drug) $21,464
- EMPLICITI (Biological) $17,726
- TUKYSA (Drug) $16,608
- BRUKINSA (Drug) $9,826
- ZEJULA (Drug) $7,545
- PIQRAY (Drug) $6,447
- Venclexta (Drug) $5,883
- TECENTRIQ (Biological) $5,299
- ZYKADIA (Drug) $4,472
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Robert Rifkin, Md, MD
Hematology & Oncology — Payments: $527,544
Hematology & Oncology $527,544
Dr. Jeffrey Matous, Md, MD
Hematology & Oncology — Payments: $357,552
Hematology & Oncology $357,552
Dr. Peter Mcsweeney, Md, MD
Hematology & Oncology — Payments: $151,717
Hematology & Oncology $151,717
Dr. Moses Raj, Md, MD
Hematology & Oncology — Payments: $135,648
Hematology & Oncology $135,648
Dr. Tara Gregory, M.d, M.D
Hematology & Oncology — Payments: $135,068
Hematology & Oncology $135,068
Peter Forsberg, Md, MD
Hematology & Oncology — Payments: $98,100
Hematology & Oncology $98,100